Toxicity of cobalt-chromium nanoparticles released from a resurfacing hip implant and cobalt ions on primary human lymphocytes in vitro

Tools

Posada, Olga M. and Tate, R. J. and Grant, M. H. (2015) Toxicity of cobalt-chromium nanoparticles released from a resurfacing hip implant and cobalt ions on primary human lymphocytes in vitro. Journal of Applied Toxicology, 35 (6). pp. 614-622. ISSN 0260-437X (https://doi.org/10.1002/jat.3100)

[thumbnail of Posada-etal-JAT-2014-Toxicity-cobalt-chromium-nanoparticles-released- from-a resurfacing-hip-implant] PDF. Filename: Posada_etal_JAT_2014_Toxicity_cobalt_chromium_nanoparticles_released_from_a_resurfacing_hip_implant.pdf
Accepted Author Manuscript
Download (602kB)

Abstract

Adverse tissue responses to prostheses wear particles and released ions are important contributors to hip implant failure. In implant-related adverse reactions T-lymphocytes play a prominent role in sustaining the chronic inflammatory response. To further understand the involvement of lymphocytes in metal-on-metal (MoM) implant failure, primary human lymphocytes were isolated and treated with CoCr wear debris and Co ions, individually, and in combination, for 24, 48, and 120h. There was a significant increase in cell number where debris was present, as measured by the Neutral Red assay. Interleukin 6 (IL-6), interferon γ (IFNγ), and tumour necrosis factor α (TNFα) secretion levels significantly decreased in the presence of metal particles, as measured by ELISA. Interleukin 2 (IL-2) secretion levels were significantly decreased by both debris and Co ions. Flow cytometry analysis showed that the metal nanoparticles induced a significant increase in apoptosis after 48h exposure. This investigation showed that prolonged exposure (120h) to metal debris induces lymphocyte proliferation, suggesting that activation of resting lymphocytes may have occurred. Although cytokine production was affected mainly by metal debris, cobalt toxicity may also modulate IL-2 secretion, and even Co ion concentrations below the MHRA guideline levels (7ppb) may contribute to the impairment of immune regulation in vivo in patients with MoM implants.

ORCID iDs

Posada, Olga M., Tate, R. J. and Grant, M. H. ORCID logoORCID: https://orcid.org/0000-0002-7712-404X;
CORE (COnnecting REpositories)